Evonile Pharma Ltd Growth Catalysts - SOIC x StockScans Report

as of Nov 2026

  1. Own distribution and field force build-out - From 1 October 2026 the full distribution network is live, with 20+ CFAs and 2,000+ stockists onboarded and \~900 medical representatives nearly all in the field by Q4 FY27, covering \~150,000 healthcare professionals. Management benchmarks a stabilized quarterly revenue base of around ₹150 crores on a Q4 FY27/Q1 FY28 footing, versus ₹56 crores in Q2 FY27 when ₹41 crores of prior-year single-customer sales had rolled off.
  2. Minipress XL cardiology acquisition - The company completed the ₹1,250 crore purchase of the Minipress trademarks from Pfizer in September 2026, adding a brand with over 50% market share and IQVIA MAT July'26 revenue of ₹228.6 crores. With \~300 of the 900 MRs dedicated to it, management expects the brand to grow ahead of its 9%-CAGR market once scaling completes over one or two quarters.
  3. Ophthalmology entry via retina portfolio - An exclusive promotion and distribution agreement signed 8 September 2026 with Novartis Healthcare adds Accentrix (ranibizumab) and Pagenax (brolucizumab) for India for an upfront ₹10 crores. This opens ophthalmology as a third therapy platform that the new specialist field force can promote from Q3 FY27 onwards.
  4. Rights issue and debt reduction - A ₹884.75 crore rights issue (₹860/share, 5-for-12) opened 19 November 2026 and closes 3 December 2026, with listing on or about 9 December 2026. Management plans to cut debt significantly by 31 March 2027, reducing finance cost from \~₹15 crores in Q3 FY27 toward ₹10-15 crores in Q4.
  5. New product introductions from Q4 FY27 - Launches of brand extensions and new products to the same specialists are set to start late Q4 FY27 or Q1 FY28 once teams stabilize, with work already underway. This lifts field-force productivity by carrying more products to each doctor without adding salesforce cost.
  6. Disciplined M&A platform - Management has stated it wants to be "very acquisitive", building on an inherited-plus-in-licensed base of roughly ₹600 crores with the intent to double it organically over 5-6 years and add acquisitions on top. The Minipress deal shows the playbook - signed and closed simultaneously in September 2026 using a capital-light balance sheet.
  7. Sourcing efficiencies and margin uplift - A dedicated team is working on sourcing efficiencies across the portfolio, with real gross-margin changes expected to show from Q1 FY28 onwards alongside mix benefits from new launches. Management targets operating and gross margins in line with comparable domestic pharma players of similar size.